Welcome to our dedicated page for Nexalin Tech SEC filings (Ticker: NXLIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nexalin Technology, Inc. (NXLIW) SEC filings page on Stock Titan provides access to regulatory documents associated with the company’s securities, including the warrants historically trading under the NXLIW symbol and the company’s common stock listed as NXL on Nasdaq. These filings offer detail on capital markets activity, listing status, and material events relevant to investors following Nexalin’s neurostimulation-focused business.
Among the key documents, a Form 8-K filed by Nexalin describes the expiration of warrants issued in connection with an initial public offering, noting that these warrants, exercisable for shares of common stock at a specified exercise price, expired by their terms and were delisted. A related Form 25 (25-NSE) filed by the Nasdaq Stock Market documents the removal from listing and registration of the warrant class identified as expiring on that date. The company has disclosed that its common stock continues to trade on the Nasdaq Capital Market under the symbol NXL.
Through Stock Titan, users can review such filings alongside other SEC reports as they become available, including current reports on material events and listing changes. The platform’s AI-powered tools are designed to summarize lengthy filings, highlight key points, and help users interpret the implications of documents like Form 8-Ks and Form 25 notices for the company’s capital structure and trading status.
For investors researching NXLIW and NXL, this page serves as a resource for understanding how warrant expirations, listing actions, and other regulatory disclosures fit into Nexalin’s broader trajectory as a developer of non-invasive, frequency-based neurostimulation devices targeting mental health and neurological conditions.
Nexalin Technology, Inc. received a notice from Nasdaq on January 21, 2026 stating that its common stock no longer meets the minimum $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. This non-compliance is based on the stock’s closing bid price over the last 30 consecutive business days.
The company has 180 calendar days, until July 20, 2026, to regain compliance by having its closing bid price at or above $1.00 per share for at least ten consecutive business days. If it fails to do so, it may qualify for a second 180-day period if it meets other Nasdaq initial listing standards apart from the bid price. If compliance is not regained, Nasdaq may move to delist the stock, although the company could appeal and would expect trading to move to an OTC Markets Group marketplace. Nexalin plans to monitor its stock price and evaluate options to regain compliance.
Nexalin Technology, Inc. reported material operational and governance details showing continued cash consumption alongside recent equity raises and Nasdaq compliance. The company lost $7.8 million from operations in 2024 and generated negative operating cash flow of $3.94 million, though it reported a working capital surplus of approximately $3.4 million. Shares outstanding increased to 13,303,523 from 7,436,562, including issuance of 3,000,000 shares to investors for net proceeds of $4.52 million and multiple share issuances to Wider and consultants for services and R&D.
The filing discloses internal control weaknesses: insufficient segregation of duties in financial reporting and inadequate IT user/superuser access controls. The company invested $96,000 in a joint venture accounted for under the equity method and wrote off a previously defaulted promissory note principal of $500,000. On July 23, 2024 Nasdaq confirmed compliance with the Minimum Stockholder Equity Rule.
Nexalin Technology, Inc. reports that its publicly traded warrants issued as part of its initial public offering have expired. On September 22, 2025, at 5:00 PM Eastern time, these warrants, each exercisable for one share of common stock at an exercise price of $4.15, terminated in accordance with their original terms.
The Nasdaq Stock Market filed a Form 25 with the SEC to reflect that the warrants had expired and were delisted. The company’s common stock is unaffected by this change and will continue to trade on the Nasdaq Capital Market under the symbol NXL.
Nexalin Technology, Inc. (symbol NXLIW) is the subject of a Form 25 notification filed under the Securities Exchange Act to remove a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing names the issuer and provides its principal office at 1776 Yorktown, Suite 550, Houston, Texas 77056 and a contact telephone number as listed in the form.
The document duplicates the regulatory checkboxes for rule provisions governing removal and states that Nasdaq certifies it has complied with the applicable procedures to strike or withdraw the class of securities. The form includes the standard OMB approval legend and a note that the Form 25 and attached notice comply with the applicable rules.